Erasca (ERAS) Other Accumulated Expenses (2020 - 2026)
Erasca posted quarterly Other Accumulated Expenses of $12.1 million for Q1 2026, up 2.31% year-on-year from $11.9 million in Q1 2025, and up 20.92% on a QoQ basis from $10.0 million in Q4 2025.
Erasca (ERAS) has 7 years of Other Accumulated Expenses data on file, last reported at $12.1 million in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 2.31% year-over-year to $12.1 million; the trailing twelve-month figure through Mar 2026 stood at $12.1 million (up 2.31% YoY), and the FY2025 full-year result was $10.0 million, down 32.46% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $12.1 million, up from $10.0 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $14.9 million in Q4 2024 and bottomed at $182000.0 in Q1 2023.
- The 5-year median for Other Accumulated Expenses is $10.8 million (2022), against an average of $9.4 million.
- The widest annual swing landed in 2022, when Other Accumulated Expenses sank 63.66%; it then jumped 4980.77% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $11.5 million in 2022, then decreased by 23.6% to $8.8 million in 2023, then soared by 68.94% to $14.9 million in 2024, then slumped by 32.46% to $10.0 million in 2025, then grew by 20.92% to $12.1 million in 2026.
- The last three Other Accumulated Expenses figures came in at $12.1 million (Q1 2026), $10.0 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.15 Mn |
| Dec 31, 2025 | 10.05 Mn |
| Sep 30, 2025 | 11.16 Mn |
| Jun 30, 2025 | 14.37 Mn |
| Mar 31, 2025 | 11.87 Mn |
| Dec 31, 2024 | 14.87 Mn |
| Sep 30, 2024 | 14.23 Mn |
| Jun 30, 2024 | 11.04 Mn |
| Mar 31, 2024 | 9.25 Mn |
| Dec 31, 2023 | 8.80 Mn |
| Sep 30, 2023 | 9.56 Mn |
| Jun 30, 2023 | 9.20 Mn |
| Mar 31, 2023 | 182,000.00 |
| Dec 31, 2022 | 11.52 Mn |
| Sep 30, 2022 | 355,000.00 |
| Jun 30, 2022 | 10.76 Mn |
| Mar 31, 2022 | 266,000.00 |
| Dec 31, 2021 | 8.96 Mn |
| Sep 30, 2021 | 977,000.00 |
| Jun 30, 2021 | 575,000.00 |
| Dec 31, 2020 | 140,000.00 |